Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD. 2011. Available from: Available at: http://www.goldcopd.org/ ( accessed 31 March, 2015).
   Google Scholar
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8): 775–789.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 mug) or salmeterol (50 mug) on COPD exacerbations. Respir Med 2008; 102(8): 1099–1108.
   PubMed Web of Science ®Google Scholar
• Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Knobil K, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6(5): 320–329.
   PubMedGoogle Scholar
• Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, RIley JH, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139(3): 505–512.
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012; 106(2): 257–268.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, Hanania N, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1(3): 210–223.
   PubMed Web of Science ®Google Scholar
• Festic E, Bansal, V, Gajic, O, Lee, AS, United States Critical Illness, Injury Trials Group: Lung Injury Prevention Study. Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc 2014; 89(2): 154–162.
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176(2): 162–166.
   PubMed Web of Science ®Google Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. Arch Intern Med 2009; 169(3): 219–229.
   PubMed Web of Science ®Google Scholar
• Chen D, Restrepo MI, Fine MJ, Pugh MJ, Anzeuto A, Metersky ML, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011; 184(3): 312–316.
   PubMed Web of Science ®Google Scholar
• de Molina RM, Mortensen EM, Restrepo MI, Copeland LA, Pugh MJV, Anzueto A. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010; 36(4): 751–757.
   PubMed Web of Science ®Google Scholar
• Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011; 38(1): 36–41.
   PubMed Web of Science ®Google Scholar
• Sellares J, Lopez-Giraldo A, Lucena C, Cilloniz C, Amaro R, Poverino E, et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013; 187(11): 1241–1248.
   PubMed Web of Science ®Google Scholar
• Liapikou A, Polverino E, Ewig S, Cillóniz C, Marcos MA, Mensa J, et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012; 39(4): 855–861.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 2010; 16(2): 118–122.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, Bourbeau J, Goldstein R, Balter M, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2007; 146(8): 545–555.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6): 912–919.
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356): 449–456.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Kuna P, Monso E, Costantini M, Petruzzelli S, Sergio F, et al. Beclomethasone/formoterol in the management of COPD: A randomised controlled trial. Respir Med 2010; 104(12): 1858–1868.
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34(3): 641–647.
   PubMed Web of Science ®Google Scholar
• Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): Results from a 52-week phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 57–71.
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144–149.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: A randomised trial. Respir Med 2013; 107(4): 550–559.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009; 69(5): 549–565.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 2012; 7: 73–86.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68(14): 1975–2000.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sorensen T, Lange P, Brix A, Tone P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999; 353(9167): 1819—1823.
   Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, Alagappan VKT, D'Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): A randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1(1): 51–60.
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE Trial. BMJ 2000; 320(7245):1297–1303.
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(5):74–81.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948–1953.
   PubMed Web of Science ®Google Scholar
• Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicenter randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351(9105):773–780.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Clinical study register. Study No. FLTA3025. Avaialble from: http://www.gskclinicalstudyregister.com/files/pdf/1231.pdf ( accessed 29 January, 2015).
   Google Scholar
• GlaxoSmithKline. Clinical study register. Study No.SCO100470. Available from: http://www.gsk-clinicalstudyregister.com/files/pdf/1079.pdf ( accessed 29 January, 2015).
   Google Scholar
• GlaxoSmithKline. Clinical study register. Study No.SCO40041. Available from: http://www.gsk-clinicalstudyregister.com/files/pdf/21086.pdf ( accessed 29 January, 2015).
   Google Scholar
• van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE Study. Am J Respir Crit Care Med 2002; 166(10):1358–1363.
   PubMed Web of Science ®Google Scholar
• Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, et al. for the COSMIC (COPD and Seretide; a Multicenter Intervention and Characterization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60(6):480–487.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wire P, Horstman D, Chang CN, Yates J, FIscher T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8):1084–1091.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 1–/25 μg) on lung function in COPD. Respir Med 2013; 107:560–569.
   PubMed Web of Science ®Google Scholar
• Cheng SL, Wang HC, Cheng SJ, Yu CJ. Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy. BMC Pulm 2011; 11: 46.
   PubMed Web of Science ®Google Scholar
• Ernst P, Suissa S. Pneumonia in elderly patients with chronic obstructive pulmonary disease. Curr Infect Dis Rep 2008; 10(3): 223–228.
   PubMedGoogle Scholar
• Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010; 104(2): 246–52.
   PubMed Web of Science ®Google Scholar
• Ko FWS, Ip M, Chan PKS, Ng SS, Chau SS, Hui DSC. A one -year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomittant pneumonia. Respir Med 2008; 102:1109–1116.
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Gray J, Edwards SJ, Morais J, Singh D. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 2011; 65(7): 764–774.
   PubMed Web of Science ®Google Scholar
• Sibila O, Anzueto A, Restrepo MI. The paradoxical effect on pneumonia of chronic inhaled corticosteroids. Clin Pulm Med 2013; 20(1): 6–10.
   Google Scholar
• Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response. JAMA 2015; 313(7):677–686.
   PubMed Web of Science ®Google Scholar
• Festic E, Scanlon P. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? Am J Respir Crit Care Med 2015; 191(2):141–148
   PubMed Web of Science ®Google Scholar
• Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014; 312(11):1114–1121.
   PubMed Web of Science ®Google Scholar